Why Is CLARIVATE PLC (CLVT) Stock Up Today?

Clarivate Plc (CLVT) shares surged 25.90% to $2.09 on Tuesday, driven by a strong third-quarter earnings report and strategic updates. The primary catalyst was the company's guidance for 10% to 15% free cash flow growth in 2027 following the completion of the sale of its Life Sciences and Healthcare business.

What Happened

Clarivate reported third-quarter results for the period ended September 30, 2026, after the market close on November 3. The company posted adjusted earnings per share of $0.21, which exceeded analyst expectations. However, revenue of $481.6 million missed forecasts, a factor that had previously weighed on the stock. CEO Matti Shem Tov and Head of Investor Relations Mark Donohue highlighted that IP ACV returned to growth as AI initiatives drove commercial momentum.

The company lowered its full-year 2026 GAAP EPS guidance from a range of $(0.64) to $(0.54) to a range of $(0.65) to $(0.62). For the fourth quarter, management projects adjusted EPS between $0.14 and $0.18, compared to estimates of $0.19. Sales are expected to range from $490.0 million to $510.0 million, against estimates of $562.824 million. The strategic sale of the LS&H division was completed, contributing to a reduction in debt.

What The Data Shows

The stock printed a fresh 52-week low on November 3, 2026, before reversing sharply. Over the last eight sessions, the stock has moved up 11.8% from $1.87 to $2.09. The 52-week range stands at $1.42 to $3.87. Clarivate remains unprofitable with a trailing twelve-month EPS of $(0.51) and a net margin of -13.8%. Revenue has declined 3.5% over the trailing twelve months. The company has a market capitalization of $1.1 billion and a beta of 1.40.

Recent insider activity includes one buy totaling $1.7 million with no sells in the last 90 days. Director Kenneth L. Cornick purchased shares on August 6, 2026.

What To Watch

Investors will monitor the company's execution on its 2027 free cash flow growth targets and the integration effects of the LS&H divestiture. The upcoming earnings release will be a key date for assessing whether the revenue decline stabilizes as AI initiatives drive commercial momentum.